Biotech Values

[DewDiligence]

…not sure which dose PFE is carrying forward

The CP-690,550 doses in all phase-3 RA trials are 5mg and 10mg.

Methotraxate ± CP-690,550 in second-line* setting:
http://clinicaltrials.gov/ct2/show/NCT00847613

CP-690,550 monotherapy vs placebo in second-line setting:
http://clinicaltrials.gov/ct2/show/NCT00814307

(CP-690,550 + methotrexate) vs (Humira + methotrexate) in second-line setting:
http://clinicaltrials.gov/ct2/show/NCT00853385

“Clinician’s choice” DMARD ± CP-690,550 in third-line setting:
http://clinicaltrials.gov/ct2/show/NCT00960440

5-year open-label extension trial (for previously enrolled patients):
http://clinicaltrials.gov/ct2/show/NCT00413699

*Whether this trial is first-line or second-line is a matter of semantics. Patients must be on methotrexate monotherapy at the time of enrollment, but they need not have progressed while on it.